$LLY

The reality is sintilimab won't be able to disrupt PD1 mkt even if approved, and $LLY knows it. 40% lower WAC alone not enough to address the elephants in US oncology practices - the sick "rebate wall" in buy-and-bill model - ASP based reimbursement that incentivize higher price https://t.co/kcLEbjTF74